Tudor Investment Corp ET AL Invests $4.11 Million in STAAR Surgical Company $STAA

Key Points

• Tudor Investment Corp ET AL bought a new position of 153,052 shares in STAAR Surgical worth about $4.11 million, representing roughly a 0.31% stake according to its latest SEC filing.
• Insider buying surged: Broadwood Partners purchased 316,017 shares (~$5.88M) and now holds 16.12M shares (~$300M), with insiders acquiring 670,213 shares in the last 90 days, signaling strong insider conviction.
• Mixed fundamentals and momentum: STAAR reported preliminary Q1 sales that more than doubled year‑over‑year and management projected about $90M for Q1—sparking a rally and a Canaccord upgrade to Buy (PT $27)—but the company remains GAAP‑unprofitable after missing recent EPS and revenue estimates.

Tudor Investment Corp ET AL purchased a new position in shares of STAAR Surgical Company (NASDAQ:STAA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 153,052 shares of the medical instruments supplier's stock, valued at approximately $4,113,000. Tudor Investment Corp ET AL owned about 0.31% of STAAR Surgical as of its most recent SEC filing.

A number of other large investors have also modified their holdings of STAA. Caitong International Asset Management Co. Ltd raised its stake in shares of STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 1,016 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of STAAR Surgical by 61.4% during the third quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 706 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 4,673 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of STAAR Surgical by 9,928.9% during the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier's stock worth $121,000 after purchasing an additional 4,468 shares during the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in shares of STAAR Surgical during the third quarter worth $199,000. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Broadwood Partners, L.P. purchased 316,017 shares of the stock in a transaction dated Friday, March 13th. The stock was bought at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the acquisition, the director owned 16,123,842 shares of the company's stock, valued at approximately $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders acquired 670,213 shares of company stock worth $12,266,249. 0.59% of the stock is currently owned by insiders.

STAAR Surgical News Roundup

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Company preliminary Q1 net sales indicate more than double year-over-year growth and management signaled a roughly $90M sales outlook for Q1, driving the rally as investors price in stronger demand and upside to estimates. Article Title
• Positive Sentiment: Multiple outlets highlight the blowout preliminary sales and upside signal from the quarter — coverage on Bloomberg, Seeking Alpha and Yahoo amplified the story and helped boost buying interest. Seeking Alpha Podcast Bloomberg
• Positive Sentiment: Canaccord Genuity upgraded STAA from Hold to Buy and raised its price target to $27, signaling stronger institutional conviction behind the sales beat and supporting further upside. MSN Article
• Neutral Sentiment: Wedbush lifted its price target to $26 but kept a Neutral rating, implying limited near-term upside from that shop and signaling some analyst caution despite the sales strength. Benzinga
• Neutral Sentiment: Wider media and “stock movers” coverage (Bloomberg, MarketWatch, Yahoo, MarketWatch lists) increased visibility and trading volume, which can amplify moves but also bring short-term volatility. Bloomberg Movers
• Negative Sentiment: STAAR remains unprofitable on a GAAP basis and earlier (March) quarterly results missed EPS and revenue expectations; analysts still model negative EPS for the year, which could limit how sustainably high multiples re-rate absent continued revenue and margin improvement.

STAAR Surgical Price Performance

STAA opened at $25.21 on Friday. The business has a fifty day simple moving average of $18.56 and a 200 day simple moving average of $22.63. The company has a market capitalization of $1.25 billion, a PE ratio of -15.47 and a beta of 1.04. STAAR Surgical Company has a 1 year low of $15.12 and a 1 year high of $30.81.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last released its earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of $0.14 by ($0.51). The company had revenue of $57.80 million for the quarter, compared to the consensus estimate of $75.54 million. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. The company's revenue for the quarter was up 18.0% on a year-over-year basis. Equities analysts anticipate that STAAR Surgical Company will post -1.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

STAA has been the topic of several recent research reports. Canaccord Genuity Group upgraded STAAR Surgical from a "hold" rating to a "buy" rating and raised their price target for the company from $22.00 to $27.00 in a report on Thursday. Morgan Stanley started coverage on STAAR Surgical in a research note on Friday, January 16th. They issued an "underweight" rating and a $13.00 target price on the stock. Wells Fargo & Company cut their target price on STAAR Surgical from $30.75 to $16.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 5th. Stifel Nicolaus cut their target price on STAAR Surgical from $19.00 to $18.00 and set a "hold" rating on the stock in a research note on Wednesday, March 4th. Finally, Jefferies Financial Group cut their target price on STAAR Surgical from $28.00 to $21.50 and set a "buy" rating on the stock in a research note on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $19.93.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.